Diamed Obesity S.R.L.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical research at Diamed Obesity S.R.L. in Galati focuses strongly on cardiovascular diseases, with studies centered on atherosclerotic cardiovascular disease, elevated lipoprotein(a), hypertension, and broader heart risk reduction. These trials are mainly designed to test new therapies that may lower major cardiovascular events and improve long-term protection for people at high risk.
- Reducing the risk of heart attack, stroke, and other major cardiovascular events
- Studying treatments for elevated lipoprotein(a) and atherosclerotic disease
- Evaluating therapies for people with cardiovascular disease and related risk factors
Several studies also look at chronic kidney disease and systemic inflammation, reflecting an integrated approach to heart and kidney health.
Digestive System Diseases
Another important area of research is digestive system diseases, especially non-alcoholic steatohepatitis and related liver fibrosis. The trials in this field aim to improve liver health, slow disease progression, and assess whether emerging treatments can reduce liver-related clinical events in people affected by metabolic liver disease.
- Testing new options for non-alcoholic steatohepatitis with fibrosis
- Assessing whether treatment can improve liver histology
- Exploring ways to lower the risk of liver-related complications
This work highlights the connection between liver disease, obesity, and broader metabolic health.
Nutritional and Metabolic Diseases
Research in nutritional and metabolic diseases is a major part of the trial portfolio, covering obesity, overweight, type 1 diabetes, type 2 diabetes, hypertriglyceridemia, and severe hypertriglyceridemia. These studies are designed to evaluate treatment effectiveness, improve blood sugar control, and address abnormal lipid levels that contribute to long-term health risks.
- Improving glycemic control in type 1 and type 2 diabetes
- Evaluating therapies for obesity and overweight
- Lowering triglycerides and managing severe lipid disorders
The site’s diabetes and cardiology focus supports research that connects metabolic disease management with prevention of cardiovascular complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Arrowhead Pharmaceuticals Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diamed Obesity S.R.L.
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia | Arrowhead Pharmaceuticals Inc. | Phase III | Not Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Empagliflozin | 3 | Unknown | 2023-08-02 | 2025-10-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.